1h Free Analyst Time
The Inhaled Nitric Oxide Market size was estimated at USD 778.21 million in 2023, USD 821.09 million in 2024, and is expected to grow at a CAGR of 5.83% to reach USD 1,157.38 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Inhaled nitric oxide (iNO) is a pulmonary vasodilator used in intensive care medicine to manage acute and chronic pulmonary disorders. It is administered through inhalation, directly reaching the lungs and improving oxygenation by dilating pulmonary blood vessels without significantly affecting blood pressure in other body parts. Its primary use is in neonatal and pediatric populations for conditions including persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). The rising incidence of neonatal conditions requiring iNO therapy, such as PPHN, and an increase in cases of ARDS have significantly propelled the need for inhaled nitric oxide.
Additionally, technological advancements enabling portable NO delivery systems have expanded the applicability of the treatments in different care settings, including home care. The ongoing research and potential new indications for iNO in adults with pulmonary diseases offer growth avenues for the market. However, the high cost and stringent regulatory requirements for approval associated with inhaled nitric oxide pose significant barriers to the entry of new players and can limit market growth. Moreover, the exploration of new therapeutic indications and innovations in administration technology that are expected to reduce costs and improve accessibility are promising areas for the inhaled nitric oxide market.
Regional Insights
In the Americas, particularly in the United States and Canada, the adoption of inhaled nitric oxide is increasing rapidly owing to the high prevalence of respiratory diseases and the strong presence of healthcare facilities with advanced technological setups. The FDA's proactive role in approving inhaled nitric oxide products for various medical conditions, including pulmonary arterial hypertension and hypoxic respiratory failure, has bolstered the growth of the inhaled nitric oxide market. Moreover, major players in the pharmaceutical and medical device industries in this region are intensively involved in R&D activities, aiming to expand the application range of inhaled nitric oxide therapy.The EMEA region exhibits a dynamic market for inhaled nitric oxide, with Europe majorly contributing to adoption and innovation. The increasing incidence of neonatal conditions and respiratory diseases in this region has heightened the need for effective therapeutic solutions, including inhaled nitric oxide. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), have laid down stringent guidelines and approval processes, ensuring the safety and efficacy of inhaled nitric oxide products. In the Middle East and Africa, the market is gradually expanding, primarily driven by healthcare infrastructure developments and growing awareness about advanced treatment modalities. The APAC region is witnessing the rapid adoption of inhaled nitric oxide therapies owing to rising healthcare expenditure, an increasing population base, and a growing number of preterm birth incidences. Countries such as China, Japan, and India are at the forefront of this adoption, driven by ongoing healthcare reforms, increasing investments in healthcare infrastructure, and rising awareness about innovative therapeutic options, including inhaled nitric oxide. Furthermore, the presence of a significant number of generic pharmaceutical manufacturers in this region offers cost-effective solutions, making inhaled nitric oxide therapy more accessible to a larger patient population.
Market Trends by Segment
- Application: Increasing incidences of chronic obstructive pulmonary disease
- End-Users: Growing deployment of inhaled nitric oxide devices in hospitals for neonatal and intensive care units
Industry Insights
- Market Dynamics
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
- FPNV Positioning Matrix
- Market Share Analysis
- Strategy Analysis and Recommendations
Recent Developments
Vero Biotech Secures USD 65 Million Credit Facility for Nitric Oxide Delivery System
Vero Biotech has secured a USD 65 million credit facility earmarked for the enhancement of its innovative nitric oxide delivery system. This strategic financial infusion is poised to revolutionize the administration of inhaled nitric oxide, a critical treatment for patients grappling with respiratory conditions. By leveraging this considerable investment, Vero Biotech aims to further refine its delivery technology, underscoring its commitment to advancing respiratory care and improving patient outcomes.Third Pole Doses First Patient in Trial with Nitric Oxide Delivery System
Third Pole Therapeutics has initiated a pioneering early feasibility trial, marking a significant advancement in the treatment of pulmonary hypertension related to interstitial lung disease (PH-ILD) with the first patient being dosed with its innovative portable inhaled nitric oxide (iNO) delivery system, the eNOfit device. This multi-center trial (NCT05867914) aims to assess the safety and tolerability of the eNOfit device, which heralds new possibilities for ambulatory treatment.Mallinckrodt Announces FDA Clearance of the INOmax EVOLVE DS Delivery System and Approval of the INOmax (Nitric Oxide) Mini-Cylinder
Mallinckrodt PLC announces the FDA clearance of its cutting-edge INOmax EVOLVE DS delivery system for administering INOmax (nitric oxide gas) for inhalation, marking a significant breakthrough in treating respiratory failure. This system is specifically designed for ventilated patients and ensures a consistent dose of nitric oxide throughout the breathing process by leveraging a unique injector module for precise synchronization and dosage.Key Company Profiles
The report delves into recent significant developments in the Inhaled Nitric Oxide Market, highlighting leading vendors and their innovative profiles. These include Air Liquide SA, Beyond Air, Inc., GE HealthCare Technologies, Inc., Getinge AB, Linde PLC, Mallinckrodt PLC, Matheson Tri-Gas, Inc. by Mitsubishi Chemical Group Corporation, Merck KGaA, NIOX Group PLC, Perma Pure LLC by Halma PLC, SOL Group, Third Pole, Inc., and VERO Biotech Inc.This research report offers invaluable insights into various crucial aspects of the Inhaled Nitric Oxide Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Inhaled Nitric Oxide Market, by Application
7. Inhaled Nitric Oxide Market, by End-Users
8. Americas Inhaled Nitric Oxide Market
9. Asia-Pacific Inhaled Nitric Oxide Market
10. Europe, Middle East & Africa Inhaled Nitric Oxide Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned
- Air Liquide SA
- Beyond Air, Inc.
- GE HealthCare Technologies, Inc.
- Getinge AB
- Linde PLC
- Mallinckrodt PLC
- Matheson Tri-Gas, Inc. by Mitsubishi Chemical Group Corporation
- Merck KGaA
- NIOX Group PLC
- Perma Pure LLC by Halma PLC
- SOL Group
- Third Pole, Inc.
- VERO Biotech Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | May 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 821.09 Million |
| Forecasted Market Value ( USD | $ 1157.38 Million |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
